WX-0593 (75 mg/kg) exhibited modest antitumor efficacy that was further enhanced in combination with QL1203 or Vectibix in both tumor models (H1975 and Ba/F3)....We also tested WX-0593, QL1203, Vectibix, and their combination in another xenograft model (Ba/F3 cells with the EGFR mutations of L858R, T790M, and C797S)....The combination of WX-0593 + QL1203 or Vectibix achieved impressive therapeutic efficacy (Figure 3)....WX-0593 exhibited a synergetic effect with an EGFR monoclonal antibody on osimertinib-resistant EGFR-mutant non-small cell lung cancer (NSCLC) both in vitro and in vivo....Their combination showed potent antitumor efficacy and an acceptable safety profile, which may be a promising strategy for the treatment of patients with EGFR triple-mutant NSCLC...